Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses

Authors: Denise da Rocha Pitta, Luis Otávio Sarian, Amilcar Barreta, Elisabete Aparecida Campos, Liliana Lucci de Angelo Andrade, Ana Maria Dias Fachini, Leonardo Martins Campbell, Sophie Derchain

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

This manuscript evaluates whether specific symptoms, a symptom index (SI), CA125 and HE4 can help identify women with malignant tumors in the group of women with adnexal masses previously diagnosed with ultrasound.

Methods

This was a cross-sectional study with data collection between January 2010 and January 2012. We invited 176 women with adnexal masses of suspected ovarian origin, attending the hospital of the Department of Obstetrics and Gynecology of the Unicamp School of Medicine. A control group of 150 healthy women was also enrolled. Symptoms were assessed with a questionnaire tested previously. Women with adnexal masses were interviewed before surgery to avoid recall bias. The Ward Agglomerative Method was used to define symptom clusters. Serum measurements of CA125 and HE4 were made. The Risk of Ovarian Malignancy Algorithm (ROMA) was calculated using standard formulae.

Results

Sixty women had ovarian cancer and 116 benign ovarian tumors. Six symptom clusters were formed and three specific symptoms (back pain, leg swelling and able to feel abdominal mass) did not agglomerate. A symptom index (SI) using clusters abdomen, pain and eating was formed. The sensitivity of the SI in discriminating women with malignant from those with benign ovarian tumors was 78.3%, with a specificity of 60.3%. Positive SI was more frequent in women with malignant than in women with benign tumors (OR 5.5; 95% CI 2.7 to 11.3). Elevated CA125 (OR 11.8; 95% CI 5.6 to 24.6) or HE4 (OR 7.6; 95% CI 3.7 to 15.6) or positive ROMA (OR 9.5; 95% CI 4.4 to 20.3) were found in women with malignant tumors compared with women with benign tumors. The AUC-ROC for CA125 was not different from that for HE4 or ROMA. The best specificity and negative predictive values were obtained using CA125 in women with negative SI.

Conclusion

Women diagnosed with an adnexal mass could benefit from a short enquiry about presence, frequency and onset of six symptoms, and CA125 measurements. Primary care physicians can be thereby assisted in deciding as to whether or not reference the woman to often busy, congested specialized oncology centers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin 2011, 61(2):134CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin 2011, 61(2):134CrossRefPubMed
3.
go back to reference Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009, 112 (3): 455-461. 10.1016/j.ygyno.2008.11.011.CrossRefPubMed Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y: Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009, 112 (3): 455-461. 10.1016/j.ygyno.2008.11.011.CrossRefPubMed
4.
go back to reference Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW: The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009, 113 (2 Pt 1): 384-394.CrossRefPubMed Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW: The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol. 2009, 113 (2 Pt 1): 384-394.CrossRefPubMed
5.
go back to reference Kaijser J, Bourne T, Valentin L, Sayasneh A, Van-Holsbeke C, Vergote I, Testa AC, Franchi D, Van-Calster B, Timmerman D: Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol. 2013, 41 (1): 9-20. 10.1002/uog.12323.CrossRefPubMed Kaijser J, Bourne T, Valentin L, Sayasneh A, Van-Holsbeke C, Vergote I, Testa AC, Franchi D, Van-Calster B, Timmerman D: Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol. 2013, 41 (1): 9-20. 10.1002/uog.12323.CrossRefPubMed
6.
go back to reference Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van-Holsbeke C, Paladini D, Van-Calster B, Vergote I, Van-Huffel S, Valentin L: Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008, 31: 681-690. 10.1002/uog.5365.CrossRefPubMed Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van-Holsbeke C, Paladini D, Van-Calster B, Vergote I, Van-Huffel S, Valentin L: Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008, 31: 681-690. 10.1002/uog.5365.CrossRefPubMed
7.
go back to reference Hartman CA, Juliato CR, Sarian LO, Toledo MC, Jales RM, Morais SS, Pitta DR, Marussi EF, Derchain S: Ultrasound criteria and CA-125 as predictive variables of ovarian cancer in women with adnexal tumors. Ultrasound Obstet Gynecol. 2012, 40 (3): 360-366. 10.1002/uog.11201.CrossRefPubMed Hartman CA, Juliato CR, Sarian LO, Toledo MC, Jales RM, Morais SS, Pitta DR, Marussi EF, Derchain S: Ultrasound criteria and CA-125 as predictive variables of ovarian cancer in women with adnexal tumors. Ultrasound Obstet Gynecol. 2012, 40 (3): 360-366. 10.1002/uog.11201.CrossRefPubMed
8.
go back to reference Vine MF, Calingaert B, Berchuck A, Schildkraut JM: Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003, 90 (1): 75-82. 10.1016/S0090-8258(03)00175-6.CrossRefPubMed Vine MF, Calingaert B, Berchuck A, Schildkraut JM: Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003, 90 (1): 75-82. 10.1016/S0090-8258(03)00175-6.CrossRefPubMed
9.
go back to reference Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR: Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007, 109: 221-227. 10.1002/cncr.22371.CrossRefPubMed Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR: Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007, 109: 221-227. 10.1002/cncr.22371.CrossRefPubMed
10.
go back to reference Bankhead CR, Kehoe ST, Austoker J: Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005, 112 (7): 857-865. 10.1111/j.1471-0528.2005.00572.x.CrossRefPubMed Bankhead CR, Kehoe ST, Austoker J: Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005, 112 (7): 857-865. 10.1111/j.1471-0528.2005.00572.x.CrossRefPubMed
11.
go back to reference Goff BA: Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012, 55 (1): 36-42. 10.1097/GRF.0b013e3182480523.CrossRefPubMed Goff BA: Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012, 55 (1): 36-42. 10.1097/GRF.0b013e3182480523.CrossRefPubMed
12.
go back to reference Van-Calster B, Timmerman D, Bourne T, Testa AC, Van-Holsbeke C, Domali E, Jurkovic D, Neven P, Van-Huffel S, Valentin L: Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst. 2007, 99 (22): 1706-1714. 10.1093/jnci/djm199.CrossRefPubMed Van-Calster B, Timmerman D, Bourne T, Testa AC, Van-Holsbeke C, Domali E, Jurkovic D, Neven P, Van-Huffel S, Valentin L: Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst. 2007, 99 (22): 1706-1714. 10.1093/jnci/djm199.CrossRefPubMed
13.
go back to reference Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N: Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer. 2008, 113: 484-489. 10.1002/cncr.23577.CrossRefPubMedPubMedCentral Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N: Combining a symptoms index with CA125 to improve detection of ovarian cancer. Cancer. 2008, 113: 484-489. 10.1002/cncr.23577.CrossRefPubMedPubMedCentral
14.
go back to reference Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M: Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012, 12 (1): 258-10.1186/1471-2407-12-258.CrossRefPubMedPubMedCentral Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M: Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012, 12 (1): 258-10.1186/1471-2407-12-258.CrossRefPubMedPubMedCentral
15.
go back to reference Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ: Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010, 203 (3): 228-e1–6CrossRefPubMedPubMedCentral Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ: Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010, 203 (3): 228-e1–6CrossRefPubMedPubMedCentral
16.
go back to reference Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N: Use of a symptom index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol. 2010, 116 (3): 378-391. 10.1016/j.ygyno.2009.10.087.CrossRefPubMed Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N: Use of a symptom index, CA125 and HE4 to predict ovarian cancer. Gynecol Oncol. 2010, 116 (3): 378-391. 10.1016/j.ygyno.2009.10.087.CrossRefPubMed
17.
go back to reference Tavassoli FA, Deville P: Pathology and genetics of tumors of the breast and female genital organs. WHO Classification of tumors. 2003, Lyon: IARC Press Tavassoli FA, Deville P: Pathology and genetics of tumors of the breast and female genital organs. WHO Classification of tumors. 2003, Lyon: IARC Press
18.
19.
go back to reference Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S: Symptoms of ovarian cancer. Obstet Gynecol. 2001, 98: 212-217. 10.1016/S0029-7844(01)01457-0.CrossRefPubMed Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S: Symptoms of ovarian cancer. Obstet Gynecol. 2001, 98: 212-217. 10.1016/S0029-7844(01)01457-0.CrossRefPubMed
20.
go back to reference Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, Mant D, Kehoe ST, Austoker J: Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008, 115 (8): 1008-1014. 10.1111/j.1471-0528.2008.01772.x.CrossRefPubMedPubMedCentral Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, Mant D, Kehoe ST, Austoker J: Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008, 115 (8): 1008-1014. 10.1111/j.1471-0528.2008.01772.x.CrossRefPubMedPubMedCentral
21.
go back to reference Ward JH: Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963, 58: 236-244. 10.1080/01621459.1963.10500845.CrossRef Ward JH: Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963, 58: 236-244. 10.1080/01621459.1963.10500845.CrossRef
22.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.CrossRefPubMed
23.
go back to reference Goff BA, Mandel L, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis. Cancer. 2000, 89 (10): 2068-2075. 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed Goff BA, Mandel L, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis. Cancer. 2000, 89 (10): 2068-2075. 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z.CrossRefPubMed
24.
go back to reference Hippisley-Cox J, Coupland C: Symptoms and risk factors to identify women with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2013, 63 (606): 11-21.CrossRef Hippisley-Cox J, Coupland C: Symptoms and risk factors to identify women with suspected cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2013, 63 (606): 11-21.CrossRef
25.
go back to reference Van-Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De-Moor B, Vergote I: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011, 5: 863-870.CrossRef Van-Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De-Moor B, Vergote I: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011, 5: 863-870.CrossRef
26.
go back to reference Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010, 102: 222-229. 10.1093/jnci/djp500.CrossRefPubMedPubMedCentral Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010, 102: 222-229. 10.1093/jnci/djp500.CrossRefPubMedPubMedCentral
27.
go back to reference Goff BA, Mandel LS, Melancon CH, Muntz HG: Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004, 291 (22): 2705-2712. 10.1001/jama.291.22.2705.CrossRefPubMed Goff BA, Mandel LS, Melancon CH, Muntz HG: Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004, 291 (22): 2705-2712. 10.1001/jama.291.22.2705.CrossRefPubMed
28.
go back to reference Kurman RJ, Shih IM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011, 42 (7): 918-931. 10.1016/j.humpath.2011.03.003.CrossRefPubMedPubMedCentral Kurman RJ, Shih IM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011, 42 (7): 918-931. 10.1016/j.humpath.2011.03.003.CrossRefPubMedPubMedCentral
29.
go back to reference Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009, 6 (7): e1000114-10.1371/journal.pmed.1000114.CrossRefPubMedPubMedCentral Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009, 6 (7): e1000114-10.1371/journal.pmed.1000114.CrossRefPubMedPubMedCentral
30.
go back to reference Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S, DOvEStudy Group: Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012, 13 (3): 285-291. 10.1016/S1470-2045(11)70333-3.CrossRefPubMed Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S, DOvEStudy Group: Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012, 13 (3): 285-291. 10.1016/S1470-2045(11)70333-3.CrossRefPubMed
31.
go back to reference Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009, 100: 1-5. 10.1038/sj.bjc.6604767.CrossRef Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009, 100: 1-5. 10.1038/sj.bjc.6604767.CrossRef
32.
go back to reference Chapron C, Santulli P, De-Ziegler D, Noel JC, Anaf V, Streuli I, Foulot H, Souza C, Borghese B: Ovarian endometrioma: severe pelvic pain is associated with deeply infiltrating endometriosis. Hum Reprod. 2012, 27: 702-711. 10.1093/humrep/der462.CrossRefPubMed Chapron C, Santulli P, De-Ziegler D, Noel JC, Anaf V, Streuli I, Foulot H, Souza C, Borghese B: Ovarian endometrioma: severe pelvic pain is associated with deeply infiltrating endometriosis. Hum Reprod. 2012, 27: 702-711. 10.1093/humrep/der462.CrossRefPubMed
Metadata
Title
Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
Authors
Denise da Rocha Pitta
Luis Otávio Sarian
Amilcar Barreta
Elisabete Aparecida Campos
Liliana Lucci de Angelo Andrade
Ana Maria Dias Fachini
Leonardo Martins Campbell
Sophie Derchain
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-423

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine